NCT06731426 is a NA clinical trial of CBM-TAF in OCD, sponsored by Han Joo Lee.

Who is sponsoring NCT06731426?

NCT06731426 is sponsored by Han Joo Lee.

What drugs are being tested in NCT06731426?

Interventions in NCT06731426: CBM-TAF, CBM-SMP.

Is NCT06731426 still recruiting?

NCT06731426 is currently recruiting now. Last updated 12 December 2024.

Last reviewed 2024-12-12 · How we verify

NCT06731426

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multi-session, Personalized Cognitive Bias Modification for Thought-Action-Fusion

Recruiting now NA Last updated 12 December 2024

What this trial tests

NA trial testing CBM-TAF in OCD in 84 participants. Currently enrolling.

Timeline

18 April 2024

Primary endpoint
31 May 2026

31 May 2026

Quick facts

Lead sponsor	Han Joo Lee
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	84
Start date	18 April 2024
Primary completion	31 May 2026
Estimated completion	31 May 2026
Sites	1 location across United States

Drugs / interventions tested

CBM-TAF
CBM-SMP

Conditions studied

OCD — all drugs for OCD →

Sponsor

Han Joo Lee

Who can join

18 and older, any sex, with OCD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Thought-Action-Fusion (TAF) is a cognitive bias that posits (1) having unwanted thoughts is morally equivalent to acting upon the thoughts (TAF-Moral; e.g., "Thinking about harming a child is as immoral as actually harming a child") and (2) having unwanted thoughts will increase the likelihood of the thoughts happening in real life (TAF-Likelihood; e.g., "My mother will get into a car accident, because I thought about it"). Given its central role in the development and maintenance of OCD, TAF has emerged as a potential treatment target for obsessive-compulsive disorder (OCD). Previous research has demonstrated that TAF is indeed a malleable construct. This study aims to examine the effects of a multi-session, personalized cognitive bias modification (CBM) for thought-action-fusion (TAF) on improving obsessive-compulsive (OC) symptoms in a college sample.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for OCD

Currently open trials in the same condition.

NCT06934525 — Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings · NA · recruiting
NCT06282146 — Testing a Transdiagnostic TMS Treatment Target · EARLY_PHASE1 · active not recruiting
NCT06978452 — Behavioural Development, Long-term Outcomes and Opportunities to Optimize Youth Mental Health Trajectories · recruiting
NCT05994053 — Neuromodulation for a Novel OCD Biomarker and Treatment · NA · recruiting
NCT06050369 — Objective Characterizatoion of Repetitive Behaviors · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06731426 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Han Joo Lee
Last refreshed: 12 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06731426.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing